Phase II study of panitumumab, nab-paclitaxel, and carboplatin followed by FEC neoadjuvant chemotherapy for patients with primary HER-2 negative inflammatory breast cancer. This is an ASCO Meeting ...
Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...
It is well known that the biggest genetic risk factor for the autoimmune disease systemic lupus erythematosus (SLE) is major histocompatibility complex class II (MHC-II). What remains unclear is the ...
Researchers found that T cells recognize neoself-antigens -- abnormal, unfolded host proteins presented by major histocompatibility complex II (MHC-II) lacking the invariant chain -- as non-self ...
News-Medical.Net on MSN
Precision mRNA vaccine strategy shows early promise for improving TNBC relapse risk
By Vijay Kumar Malesu A pioneering personalized mRNA vaccine study reveals lasting immune responses in triple-negative breast cancer, offering early signals that tailored cancer vaccination may help ...
Background: We have shown that the high prevalence of HLA-A2 in Scandinavia is associated to poor prognosis in advanced (stage III-IV) serous adenocarcinoma of the ovary. Our objective was to analyse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results